Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple supplement shield kidneys from disease?

NCT ID NCT06441435

Disease control Sponsor: Taichung Veterans General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study tested whether adding AC-134, a dietary supplement, to a low-protein diet helps protect kidney function in people with chronic kidney disease. Researchers measured kidney function, protein in urine, and waste products in the blood of 100 adults aged 20-90 with stage 3-5 disease. The goal was to see if this combination could slow kidney damage and improve overall health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AC-134 (a dietary supplement) combined with a low-protein diet
What this could lead to
If it works, this could point toward a simple dietary supplement that helps slow kidney decline in chronic kidney disease patients.
What could go wrong
This is a small, completed trial with no phase designation, so results may not be conclusive. The supplement's benefits are uncertain and may not apply to all kidney disease patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Jun 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 20-90 years. * Diagnosed with stage 3-5 chronic kidney disease, excluding dialysis patients. * Signed informed consent is required before enrollment. Exclusion Criteria: * Use of other brand-activated charcoal supplements during the study period. * Pregnant or lactating women. * Patients who have undergone kidney transplantation. * Obstructive nephropathy within the past month. * Acute kidney injury within the past three months. * Gastrointestinal bleeding or severe constipation within the past three months. * Patients with active malignancy within the past two years. * Severe cardiovascular diseases such as congestive heart failure New York class III-IV or cerebrovascular disease * Severe liver disease, such as liver cirrhosis with ascites. * Active infectious disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anthrax infection chronic kidney disease chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nephrology

Contacts and locations

Locations

  • Taichung Veterans General Hospital

    Taichung, ROC, 40705, Taiwan

  • Taichung Veterans General Hospital.

    Taichung, ROC, 40705, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.